| abstract |
Provided is a pharmaceutical product for the purpose of preventing and / or treating benign prostatic hypertrophy (BPH) and associated symptoms. Use of 1-α-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-cholecalciferol, or a pharmaceutically acceptable salt or ester thereof. In addition, it contains an α-adrenergic receptor blocker as the second BPH-active substance, and the α-adrenergic receptor blocker is selected from terazosin, doxazosin, tamsulosin, silodosin, AIO-8507L and RBx-2258 Medicines. [Selection figure] None |